Patients with neovascular age-related macular degeneration (nAMD) who receive intravitreal ranibizumab injections on an individualized schedule have the same visual acuity gains as patients treated on a standard monthly schedule, and individualized plans reduce the number of office visits and injections, according to a single-institution phase 4 study. Irmela Mantel, MD, from the Ophthalmology Department at the University of Lausanne, Jules-Gonin Eye Hospital, in Switzerland, presented the study results at the 12th EURETINA Congress held in Milan, Italy. Antivascular endothelial growth-factor agents have revolutionized the treatment of nAMD and brought about dramatic improvements in visual acuity in these patients.To see more details visit,www.medscape.com